Cas:1869-27-8 [4-(trifluoromethyl)phenyl]phosphonic acid manufacturer & supplier

Chemical Name:[4-(trifluoromethyl)phenyl]phosphonic acid

CAS.NO:1869-27-8

Synonyms:[4-(trifluoromethyl)phenyl]phosphonic acid

Molecular Formula:C₇H₆F₃O₃P

Molecular Weight:226.09000

HS Code:2931900090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:67.34000

Exact Mass:226.00100

LogP:1.50840

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like [4-(trifluoromethyl)phenyl]phosphonic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,[4-(trifluoromethyl)phenyl]phosphonic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[4-(trifluoromethyl)phenyl]phosphonic acid Use and application,[4-(trifluoromethyl)phenyl]phosphonic acid technical grade,usp/ep/jp grade.

Related News: There’s still hope for this approach to treating Alzheimer’s disease despite the somewhat mixed results from this trial, said Rebecca Edelmayer, senior director of scientific engagement at the Alzheimer’s Association. [4-(trifluoromethyl)phenyl]phosphonic acid manufacturer The United States has suspended imports of dogs from more than 100 countries where there’s a high rabies risk. [4-(trifluoromethyl)phenyl]phosphonic acid supplier The South Korean government is banning entry to all foreign nationals who visited China’s Hubei province in the past 14 days. [4-(trifluoromethyl)phenyl]phosphonic acid vendor Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. [4-(trifluoromethyl)phenyl]phosphonic acid factory Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma.